McKay, R. R., Armstrong, A. J., Emamekhoo, H., Gourdin, T. S., Heath, E. I., Hussain, A., … Royal, M. A. (2023). The Maverick trial: A phase 2 study of abivertinib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

McKay, Rana R., Andrew J. Armstrong, Hamid Emamekhoo, Theodore Stewart Gourdin, Elisabeth I. Heath, Arif Hussain, Moshe Chaim Ornstein, et al. “The Maverick trial: A phase 2 study of abivertinib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

McKay RR, Armstrong AJ, Emamekhoo H, Gourdin TS, Heath EI, Hussain A, et al. The Maverick trial: A phase 2 study of abivertinib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

McKay, Rana R., et al. “The Maverick trial: A phase 2 study of abivertinib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

McKay RR, Armstrong AJ, Emamekhoo H, Gourdin TS, Heath EI, Hussain A, Ornstein MC, Sharifi N, Viscuse PV, Yan Y, Royal MA. The Maverick trial: A phase 2 study of abivertinib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). JOURNAL OF CLINICAL ONCOLOGY. 2023.